Superficial urothelial cancer in the prostatic urethra

Creative Commons License

Kirkali Z., Canda A. E.

THESCIENTIFICWORLDJOURNAL, vol.6, pp.2603-2610, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 6
  • Publication Date: 2006
  • Doi Number: 10.1100/tsw.2006.402
  • Journal Name: THESCIENTIFICWORLDJOURNAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2603-2610
  • Keywords: bladder cancer, superficial bladder tumors, prostatic urethral tumor, transitional cell carcinoma, TRANSITIONAL-CELL-CARCINOMA, BACILLUS-CALMETTE-GUERIN, POSITIVE URINARY CYTOLOGY, BLADDER-CANCER, INTRAVESICAL THERAPY, TRANSURETHRAL RESECTION, TUMOR RELAPSE, IN-SITU, INVOLVEMENT, MANAGEMENT
  • Dokuz Eylül University Affiliated: No

Abstract

Transitional cell carcinoma (TCC) is a multifocal disease of the urinary tract that can also involve the prostatic urethra (PU). The exact incidence of superficial involvement of the PU in patients with bladder TCC is not well known. Bladder TCC may involve the prostate in 12-40% of the patients and the degree of involvement can include urethral mucosa, ducts, acini, and stroma of the gland, which has been shown to affect the outcome. Risk factors for superficial urothelial cancer in the PU are high-grade, multifocal bladder TCC and presence of carcinoma in situ (CIS) in the bladder. While visible tumors are easy to detect and resect, controversy still exists regarding the optimal technique to identify prostatic involvement by TCC. Prostatic urethral sampling by a transurethral resection biopsy or a cold-cup biopsy, particularly in the high-risk group of bladder cancer patients, has been recommended for detecting prostatic urethral involvement. Management of superficial prostatic involvement by TCC is also unclear. Currently, there is increasing recognition of the value of conservative treatment options with intravesical agents when there is superficial involvement of the PU. Particularly, intravesical bacillus Calmette-Guerin (BCG) seems to be an effective treatment alternative in the management of superficial involvement of the PU by TCC. Close follow-up by cystoscopy and PU biopsy at 3-month intervals, particularly in intermediate and high-risk patients who respond to intravesical therapy and in whom cystectomy is appropriate, is recommended in order to detect persistent tumor, recurrences, or progression.